{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-097500","form_type":"8-K","ticker":"CARM","cik":"0001485003","company_name":"Carisma Therapeutics Inc.","filed_at":"2023-09-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.057537+00:00","generated_at":"2026-06-11T00:28:55.818456+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Carisma Therapeutics Reports Phase 1 CT-0508 Data Showing Safety and Biomarker Correlation","bullets":["CT-0508 is a HER2-targeted CAR-M therapy for HER2 overexpressing cancers; 14 patients treated across group 1 (n=9) and group 2 (n=5).","Group 1: best overall response of stable disease in 4 of 9 patients; group 2: best overall response was progressive disease.","No dose-limiting toxicities reported; CT-0508 well-tolerated after single-day bolus infusion in group 2.","Translational analyses combining groups show correlation between TME activation, T cell activation, and HER2 status with stable disease.","Company to focus on combination sub-study with pembrolizumab due to T cell exhaustion findings from trial."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-097500","json":"https://secwatch.observer/filing/0001104659-23-097500.json","markdown":"https://secwatch.observer/filing/0001104659-23-097500.md","text":"https://secwatch.observer/filing/0001104659-23-097500.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1485003/000110465923097500/0001104659-23-097500-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1485003/000110465923097500/tm2325287d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T00:28:55.818456+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}